Browse > Article

Synthesis of 6-amino-2-N-(n-propionylamino)selenazolo[4,5-f]indan  

Kim, Min-Kyeom (College of Pharmacy, Catholic University of Daegu)
Ma, Eun-Sook (College of Pharmacy, Catholic University of Daegu)
Publication Information
YAKHAK HOEJI / v.52, no.1, 2008 , pp. 20-26 More about this Journal
Abstract
2-Aminothiazole ring as a bioisoster of catechol in dopamine has provided with good oral availability and lipophilic property. Selenium was reported to have an improved antioxidant ability and to reduce the loss of dopamine. 2-Aminoindan, is a rigid form of dopamine, was evaluated as a dopamine agonist with low neurotoxocity. In order to develop a novel dopamine agonist, we tried to synthesize the selenazoloaminoindan derivative that is a hybrid structure of aminoindan and aminoselenazole instead of aminothiazole. 2-Indanone-2-oxime was reduced with $TiCl_4$ and $NaBH_4$ to form 2-aminoindan, which was reacted with propionyl chloride to give 2-N-n-propionylaminoindan (2). Compound 2 was reduced with $TiCl_4$ and $NaBH_4$ to afford 2-N-n-propylaminoindan (3) and it was nitrated and reduced to form 5-amino-2-N-n-propylaminoindan (5), which was reacted with KSeCN, $Br_2$, and glacial acetic acid to give 4,6-dibromo-5- amino-2-N-n-propylaminoindan (7) instead of selenazole ring formation. Otherwise, compound 2 was nitrated and hydrogenated to form 5-amino-2-N-n-propionylaminoindan (9), which was treated with KSeCN, $Br_2$, and glacial acetic acid to give 4,6-dibromo-5-amino-2-N-n-propionylaminoindan (10). Compound 9 was cyc1ized with KSeCN and glacial acetic acid in the absence of $Br_2$ to give 6-amino-2-N-(n-propionylamino)selenazolo[4,5-f]indan (11).
Keywords
Parkinson's disease; selenazoloaminoindan; dopamine $D_3$ agonist;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Jackson, D. M. and Westlind-Danielsson, A. : Dopamine receptors: Molecular biology, biochemistry and behavioural aspects. Pharmacol. Ther. 64, 291 (1994)
2 Jaen, J. C., Wise, L. D., Caprathe, B. W., Tecle, H., Bergmeier, S., Humblet, C. C., Heffner, T. G., Meltzer, L. T. and Pugsley, T. A. : 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties. J. Med. Chem. 33, 311 (1990)
3 Haadsma-Svensson, S. R., Cleek, K. A., Dinh, D. M., Duncan, J. N., Haber, C. L., Huff, R. M., Lajiness, M. E., Nichols, N. F., Smith, M. W., Svensson, K. A., Zaya, M. J., Carlsson, A. and Lin, C.-H. : Dopamine $D_3$ receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyland N-alkylary-l-substituted-2-aminoindans. J. Med. Chem. 44, 4716 (2001)
4 Zafar, K. S., Siddiqui, A., Sayeed, I., Ahmad, M., Salim, S. and Islam, F. : Dose-dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidence. J. Neurochem. 84, 438 (2003)
5 Kano, S., Tanaka, Y., Sugino, E. and Satsoshi, H. : Reduction of some functional group with titanium (IV) chloride/sodium borohydride. Synthesis 695 (1980)
6 Valerie, A., Adrian, N.-T., Gobert, L., Rivet, J.-M., Brocco, M., Lejeune, F., Gluck, L., Desposte, I., Bervoets, K., Dekeyne, A. and Millan, M. J. : A comparative in vitro and in vivo pharmacological characterization of the novel dopamine $D_3$ receptor antagonists (+)-S 14297, Nafadotride, GR 103,691 and U 99194. Pharmacol. Exp. Ther. 287(1), 187 (1998)
7 Castano, A., Cano, J. and Machado, A. : Low selenium diet effects monoamine turnover differentially in substantia nigra and striatum. J. Neurochem. 61, 1302 (1993)
8 Levant, B. : The $D_3$ dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol. Rev. 49(3), 231 (1997)
9 Mierau, J., Schneider, F. J., Ensinger, H. A., Chio, C. L., Lajiness, M. E. and Huff, R. M. : Pramipexole binding and activation of cloned and expressed dopamine $D_2$, $D_3$ and $D_4$ receptor. Eur. J. Pharmacol. 290, 29 (1995)
10 Boadi, W. Y., Taire, L., Kerem, D. and Yannai, S. : Effect of dietary supplementation with vitamin E, ribofalvin and selenium on central nervouse system oxygen toxicity. Pharmacol. Toxicol. 68, 77 (1991)
11 Cassarino, D. S., Fall, C. P., Swerdlow, R. H., Smith, T. S., Halvorsen, E. M., Miller, S. W., Park, J. P., Parker, W. D. Jr. and Bennett, J. P. Jr. : Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta. 1362, 77 (1997)
12 Hall, E. D., Andrus, P. K., Oostveen, J. A., Althaus, J. S. and Vonvoigtlander, P. F. : Neuroprotective effects of the dopamine $D_2$/$D_3$ agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 742, 80 (1996)
13 Huang, K., Lauridsen, E. and Clausen, J. : Localization of new glutathione peroxidases in rat brain. Biol. Trace Elem. Res. 46, 91 (1994)
14 Kebabian, J. W. and Calne, D. B. : Multiple receptors for dopamine. Nature 277, 93 (1979)
15 Bonne, C., Latour, E., Muller, P., Kozak, Y., Faure, J. P., Malet, F., Colin, J., Tissot, M., Giroud, J. P., Maghni, K., Griswold, D. E. and Coquelet, C. : 2-(2-Hydroxy-4-methylphenyl)aminothiazole hydrochloride as a dual inhibitor of cyclooxygenase and a free radical scanvenger. 2nd communication: anti-inflammatory activity. Arzneimittelforschung 39, 1246 (1981)
16 Stjernlof, P., Ennis, M. D., Hansson, L. O., Hoffman, R. L., Ghazal, N. B., Sundell, S., Smith, M. W., Svensson, K., Carlsson, A. and Wikstrom, H. : Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz e indole ring system. Part 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes. J. Med. Chem. 38, 2202 (1995)
17 Bouthenet, M. L., Souil, E., Martres, M. P., Sokoloff, P., Giros, B. and Schwartz, J. C. : Localization of a dopamine $D_3$ receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine $D_2$ receptor mRNA. Brain Res. 564, 203 (1991)
18 James, P. B. Jr. and Montford, F. P. : Pramipexole - a new dopamine agonist for the treatment of Parkinson's disease. J. Neuro. Sci. 163, 25 (1999)
19 Emilien, G., Maloteaux, J.-M., Geurts, M., Hoogenberg, K. and Cragg, S. : Dopamine receptors - physiological understanding to therapeutic intervention potential. Pharmacol. Ther. 84, 133 (1999)
20 Imam, S. Z., Newport, G. D., Islam, F., Sliker, W. Jr. and Ali, S. F. : Selenium, an antioxidant, protects against methampetamine-induced dopaminergic neurotoxicity. Brain Res. 818, 575 (1999)
21 Racane, L., Stojkovic, R., Tralic-Kulenovic, V. and Karminski-Zamola, G. : Synthesis and antitumor evaluation of novel derivatives of 6-amino-2-phenylbenzothiazoles. Molecules 11, 325 (2006)